FFO
CMPX icon

Fortitude Family Office’s Compass Therapeutics CMPX Stock Holding History

Fortitude Family Office’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.24K Sell
1,481
-434
-23% -$1.28K ﹤0.01% 1280
2026
Q1 		$10.1K Sell
1,915
-2,676
-58% -$15.4K ﹤0.01% 654
2025
Q4 		$24.7K Sell
4,591
-387
-8% -$1.79K 0.01% 359
2025
Q3 		$17.4K Sell
4,978
-5
-0.1% -$16 ﹤0.01% 424
2025
Q2 		$13K Sell
4,983
-162
-3% -$334 ﹤0.01% 479
2025
Q1 		$9.78K Hold
5,145
– – ﹤0.01% 540
2024
Q4 		$7.46K Buy
5,145
+3,313
+181% +$5.5K ﹤0.01% 717
2024
Q3 		$3.37K Buy
+1,832
New +$2.28K ﹤0.01% 901

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Fortitude Family Office's CMPX Position: Q2 2026 in Review

Fortitude Family Office reduced its Compass Therapeutics (CMPX) stake by 23% in Q2 2026, selling an estimated $1.28K and leaving 1,481 shares worth $3.24K. The position accounts for ﹤0.01% of the portfolio, ranked #1280.

Fortitude Family Office first reported a position in CMPX in Q3 2024 and has held it in 8 quarters since. The position peaked at $24.7K in Q4 2025. 215 funds tracked by Wall St. Rank hold CMPX as of Q2 2026.

  • Fortitude Family Office held 1,481 shares of Compass Therapeutics worth $3.24K as of Q2 2026.
  • Fortitude Family Office sold 434 Compass Therapeutics shares in Q2 2026, an estimated $1.28K.
  • Compass Therapeutics made up ﹤0.01% of Fortitude Family Office's portfolio in Q2 2026, its #1280 holding.
  • Fortitude Family Office first reported a position in Compass Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • Fortitude Family Office's Compass Therapeutics position peaked at $24.7K in Q4 2025.
  • 215 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2026.

Based on Fortitude Family Office's 13F filing for Q2 2026, filed 20 Jul 2026.